The correct choice of pharmaceutical interventions for Parkinsonism management results in a better patient outcome and reduced occurrence of motor complications. This guideline outlines the efficacy and the adverse effects of the available class of drugs for pharmacotherapy of parkinsonism. Parkinsonism is characterized by tremor, bradykinesia, rigidity and postural instability.
Treatment strategies of parkinsonism depend on the patient’s age, disease stage, most troublesome symptoms, the balance between efficacy, and other factors. However, it is important to base treatment decisions on the best available data for each intervention. Practical guideline for the adjustment of initial therapy in patients without motor complications Patients not on dopaminergic therapy: If a patient has started on an MAO-B inhibitor, anticholinergic, amantadine or a combination of these, a stage will come…
